Online citations, reference lists, and bibliographies.
← Back to Search

Radiolabeled Bombesin Analogs For Prostate Cancer Diagnosis: Preclinical Studies.

B. Faintuch, R. Teodoro, A. Duatti, E. Muramoto, Salomão Faintuch, C. J. Smith
Published 2008 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION Radionuclide imaging can be a useful tool for the diagnosis of prostate cancer. Bombesin (BBN) is a molecule with high affinity for gastrin releasing peptide (GRP) receptors which are over-expressed in that tumor. This report compares (99m)Tc-HYNIC-betaAla-BBN(7-14)NH2 [(99m)Tc-HYNIC-BBN] and (99m)Tc identical withN(PNP6)-Cys-betaAla-BBN(7-14)NH2 [(99m)TcN(PNP6)-Cys-BBN] with regard to labeling procedures as well as in vitro and in vivo evaluation (biodistribution and scintigraphic imaging). METHODS Peptide synthesis was performed in an automated peptide synthesizer. HYNIC-BBN was radiolabeled with pertechnetate using tricine and ethylenediamine diacetic acid (EDDA) as coligands. Cys- BBN was radiolabeled in a two-step procedure with the preparation of the precursor (99m)Tc-Nitrido first and then introducing diphosphine (PNP6). Radiochemical evaluation of conjugates, as well as studies of stability, transchelation toward cysteine, and partition coefficient were done. Biological studies included internalization, biodistribution in healthy animals and in animals bearing PC3 cancer cells with acquisition of images from the tumor-bearing animals. RESULTS Both complexes showed a high radiochemical yield along with good stability. Biodistribution studies pointed out strong renal excretion for the former complex due to its hydrophilic profile and marked hepatobiliary excretion for the latter, corresponding to observed lipophilicity. Tumor uptake was higher for (99m)Tc-HYNIC-BBN and the same occurred with internalization findings, which exceeded those of (99m)TcN(PNP6)-BBN. Blocking studies in mice bearing PC-3 tumor cells revealed significantly reduced pancreas and tumor uptake, demonstrating receptor specificity of the conjugates. CONCLUSION The best radiotracer was (99m)Tc-HYNIC-BBN on the basis of high radiochemical yield, fast radiolabeling procedure without need for a purification step, and more consistent tumor uptake.
This paper references
10.1016/J.NUCMEDBIO.2004.02.009
New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides.
D. Blok (2004)
10.1081/SIM-200047545
99mTc‐HYNIC‐Bombesin (7‐14)NH2: Radiochemical Evaluation with Co‐ligands EDDA (EDDA = Ethylenediamine‐N,N′‐diacetic Acid), Tricine, and Nicotinic Acid
B. Faintuch (2005)
10.1007/s00259-002-1040-x
[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging
B. Nock (2002)
10.1093/ANNONC/MDM058
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.
D. B. Cornélio (2007)
10.1053/SNUC.2001.26205
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
S. Banerjee (2001)
10.2174/0929867003374516
Receptor targeting for tumor localisation and therapy with radiopeptides.
A. Heppeler (2000)
10.1021/BC980096A
99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent.
S. Karra (1999)
A new efficient method for the preparation of 99 mTc - radiopharmaceuticals containing the Tc ≡ N multiple bond , Int
R Pasqualini (1992)
10.1016/J.NUCMEDBIO.2005.05.005
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
C. J. Smith (2005)
10.1016/J.NUCMEDBIO.2006.10.004
Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues.
E. García Garayoa (2007)
Substitution reactions of 99 mTcNCl 4 - , a new route to a new class of 99 mTc - radiopharmaceuticals
J Baldas (1985)
10.1097/00006231-200006000-00078
Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.
C. Van de Wiele (2001)
10.1016/0883-2889(92)90004-X
A new efficient method for the preparation of 99mTc-radiopharmaceuticals containing the TcN multiple bond
R. Pasqualini (1992)
10.1074/JBC.271.13.7731
There Are Three Distinct Forms of Bombesin
S. R. Nagalla (1996)
10.1016/S0969-8051(03)00116-1
Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.
C. J. Smith (2003)
10.1021/BC034100G
The [(99m)Tc(N)(PNP)](2+) metal fragment: a technetium-nitrido synthon for use with biologically active molecules. The N-(2-methoxyphenyl)piperazyl-cysteine analogues as examples.
C. Bolzati (2003)
Imaging adenoviral-mediated gene transfer of gastrin releasing peptide receptor (GRPr) using a Tc-99m-labeled bombesin (BBN) analogue
KR Zinn (1998)
10.1007/BF02145873
Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the european amphibiansBombina andAlytes
A. Anastasi (2005)
Tc-HYNIC-bombesin (7-14)NH2: Radiochemical evaluation with co-ligands EDDA (EDDA=ethylenediamine-N,N′-diacetic acid), tricine, and nicotinic acid
BL Faintuch (2005)
10.1016/S0969-8051(02)00311-6
Synthesis and biodistribution of a new (99m)Tc nitrido complex for cerebral imaging.
J. Zhang (2002)
10.1002/CHIN.200428247
Peptide‐Based Radiopharmaceuticals: Future Tools for Diagnostic Imaging of Cancers and Other Diseases
S. Okarvi (2004)
10.1016/S0969-8051(01)00209-8
Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells.
T. Hoffman (2001)
10.1021/CR980436L
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
In vitro and in vivo evaluation of a Tc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptorpositive tumors
R La bella (2002)
Radiochemical investigations of 99mTc-N3S-X-BBN [7-14]NH2: an in vitro/in vivo structure-activity relationship study where X
CJ Smith (2003)
Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
T. Maina (2005)
Tc]Demobesin 1, a novel potent bombesin analogue for 411 B.L
B Nock (2008)
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
R. Markwalder (1999)
10.1016/0020-708X(85)90228-5
Substitution reactions of 99mTcNCl-4--A route to a new class of 99mTc-radiopharmaceuticals.
J. Baldas (1985)
10.1007/s002590000355
Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study
C. van de Wiele (2000)
10.1021/BC700197M
Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
J. Kunstler (2007)
10.1016/S0969-8051(02)00314-1
In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors.
R. La Bella (2002)
10.2967/jnumed.107.045054
Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
R. Cescato (2008)
10.1021/BC020034R
Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
C. J. Smith (2003)



This paper is referenced by
10.1007/s10967-013-2464-4
Evaluation of a new radiolabeled bombesin derivative with 99mTc as potential targeted tumor imaging agent
N. Sadeghzadeh (2013)
10.18869/ACADPUB.RMM.4.3.3
Targeted Cancer Diagnostic and Therapeutic Agents: Delivery by Carriers or Conjugation
Mohsen Mohammadgholi (2016)
10.1016/j.apradiso.2012.06.022
Kit formulation for 99mTc-labeling of HYNIC-βAla-Bombesin((7-14)).
A. L. B. de Barros (2012)
[Lys,Tyr] bombesin (3-14) for Prostate Cancer Detection
H. Omrani (2017)
10.1177/147323001204000401
New Agonist- and Antagonist-Based Treatment Approaches for Advanced Prostate Cancer
Y. Xu (2012)
10.1097/MNM.0000000000000449
Feasibility study with 99mTc-HYNIC-&bgr;Ala-Bombesin(7–14) as an agent to early visualization of lung tumour cells in nude mice
Lucas L. Marostica (2016)
10.1007/s00259-011-2001-z
Radiopharmaceutical development of radiolabelled peptides
M. Fani (2011)
10.1166/JBN.2015.1910
Bombesin Encapsulated in Long-Circulating pH-Sensitive Liposomes as a Radiotracer for Breast Tumor Identification.
A. L. B. de Barros (2015)
10.1038/srep33511
Investigation of SP94 Peptide as a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy
Yanli Li (2016)
10.1021/bc800475k
Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
E. Fragogeorgi (2009)
10.1590/S1807-59322011000200024
Radiolabeled nano‐peptides show specificity for an animal model of human PC3 prostate cancer cells
B. Faintuch (2011)
10.1039/b814903h
Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.
M. Bartholomae (2009)
10.1088/0957-4484/26/19/195101
Breast cancer photothermal therapy based on gold nanorods targeted by covalently-coupled bombesin peptide.
Zahra Heidari (2015)
10.1016/j.nucmedbio.2012.01.002
Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
S. Okarvi (2012)
10.1002/anie.201105547
Strain-promoted copper-free "click" chemistry for 18F radiolabeling of bombesin.
Lachlan S. Campbell-Verduyn (2011)
10.1590/1414-431X20154506
Evaluation of 99mTc-HYNIC-βAla-Bombesin(7-14) as an agent for pancreas tumor detection in mice.
F.N. Carlesso (2015)
10.1016/j.peptides.2017.01.002
Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor
K. De (2017)
Development of Radiolabelled Bombesin Analogues for Imaging Prostate Cancer with SPECT and PET
Z. Yu (2014)
Synthesis of the Nontargeted Nanoconstructs Stabilized with DTDTPA or TDOTA and the Respective Peptide Conjugated and / or Radiolabeled Particles Bioconjugate Chemistry
Francisco Silva (2016)
10.3109/1061186X.2012.757772
In vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines
F. Yurt Lambrecht (2013)
10.1007/s10967-012-2331-8
99mTc-labeled bombesin analog for breast cancer identification
A. Barros (2012)
10.1016/j.bmcl.2010.08.124
Bombesin derivative radiolabeled with technetium-99m as agent for tumor identification.
A. L. B. de Barros (2010)
10.1097/MNM.0000000000000505
Preliminary data of the antipancreatic tumor efficacy and toxicity of long-circulating and pH-sensitive liposomes containing cisplatin
F. Carlesso (2016)
10.1002/9780470613214.CH10
Viral Introduction of Receptors for Targeted Radiotherapy
Kathryn Ottolino-Perry (2010)
New Freeze-dried Kit for Diagnosis of Bombesin Receptor Expressing Tumors
E. Mostafa (2010)
10.6061/clinics/2012(02)12
Comparison of two peptide radiotracers for prostate carcinoma targeting
B. Faintuch (2012)
10.1038/ijo.2015.204
Wheat gluten intake increases weight gain and adiposity associated with reduced thermogenesis and energy expenditure in an animal model of obesity
R. Freire (2016)
10.1021/jm900360d
Structural assessment and biological evaluation of two N3S bombesin derivatives.
Eleni Gourni (2009)
10.1186/1471-2180-12-28
Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis
Diego C P Rossi (2011)
Radiofarmaci "metal based" nella cardiologia nucleare e nell'imaging tumorale
D. Carta (2012)
10.1007/s10967-014-3040-2
Evaluation of the optimal LNCaP prostate tumour developmental stage to be assessed by 99mTc-HYNIC-βAla-Bombesin(7–14) in an experimental model
L. L. Fuscaldi (2014)
10.1016/j.jphotobiol.2013.10.019
Gold nanorods-bombesin conjugate as a potential targeted imaging agent for detection of breast cancer.
Zahra Heidari (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar